STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial
The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.
The US FDA has approved a treatment for ataxia-telangiectasia, a rare genetic disease. According to Endpoints News, the treatment, Aqneursa, is from privately held biotech IntraBio.
No further details on the treatment or the company were provided in the reports.
In separate news, Novo Nordisk outlined plans to expand its pipeline and find new products, aiming to launch at least five multi-blockbusters by 2030, as reported by STAT News. The company's CEO, Mike Doustdar, presented a strategy to invest more in disease areas outside diabetes and obesity and to be more active in business development.
Brief written by urgent.news from Endpoints News, STAT News — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
